Breast Cancer

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses caveats of the PERSEPHONE trial.

The FDA has approved the Magtrace and Sentimag Magnetic Localization System used to guide lymph node biopsies in women undergoing mastectomy for breast cancer.

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine and Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

Researchers remain keenly interested in exploring PIK3CA as an anticancer target in breast cancer.